These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34117987)

  • 21. Regulatory and HTA early dialogues in medical devices.
    Blankart CR; Dams F; Penton H; Kaló Z; Zemplényi A; Shatrov K; Iskandar R; Federici C
    Health Policy; 2021 Oct; 125(10):1322-1329. PubMed ID: 34353636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health technology assessment: research trends and future priorities in Europe.
    Nielsen CP; Funch TM; Kristensen FB
    J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TAXONOMY OF MEDICAL DEVICES IN THE LOGIC OF HEALTH TECHNOLOGY ASSESSMENT.
    Henschke C; Panteli D; Perleth M; Busse R
    Int J Technol Assess Health Care; 2015 Jan; 31(5):324-30. PubMed ID: 26711471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries.
    Efthymiadou O; Kanavos P
    Int J Technol Assess Health Care; 2021 Jan; 37():e31. PubMed ID: 33509311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the economic tools for assessing new medical devices.
    Craig JA; Carr L; Hutton J; Glanville J; Iglesias CP; Sims AJ
    Appl Health Econ Health Policy; 2015 Feb; 13(1):15-27. PubMed ID: 25139635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA.
    Janssens R; Russo S; van Overbeeke E; Whichello C; Harding S; Kübler J; Juhaeri J; Bywall KS; Comanescu A; Hueber A; Englbrecht M; Nikolenko N; Pravettoni G; Simoens S; Stevens H; Hermann R; Levitan B; Cleemput I; de Bekker-Grob E; Veldwijk J; Huys I
    Patient; 2019 Oct; 12(5):513-526. PubMed ID: 31222436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal.
    Pongiglione B; Torbica A; Blommestein H; de Groot S; Ciani O; Walker S; Dams F; Blankart R; Mollenkamp M; Kovács S; Tarricone R; Drummond M
    Int J Technol Assess Health Care; 2021 Apr; 37(1):e62. PubMed ID: 33896433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health technology assessment of medical devices: a survey of non-European union agencies.
    Ciani O; Wilcher B; Blankart CR; Hatz M; Rupel VP; Erker RS; Varabyova Y; Taylor RS
    Int J Technol Assess Health Care; 2015 Jan; 31(3):154-65. PubMed ID: 26044729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
    Maynou L; Cairns J
    Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EVIDENCE REQUIREMENTS FOR REIMBURSEMENT OF PHARMACEUTICALS ACROSS EUROPE.
    Oyebode O; Garrett Z; George E; Cangini A; Muscolo LA; Warren S; Nemeth B; Földesi C; Heislerová M; Gajdošová E
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):59-67. PubMed ID: 26168803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
    Polisena J; Jayaraman G
    Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN EUROPE: PROCESSES, PRACTICES, AND METHODS.
    Fuchs S; Olberg B; Panteli D; Busse R
    Int J Technol Assess Health Care; 2016 Jan; 32(4):246-255. PubMed ID: 27670589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation Road Map of Health Technology Assessment in Middle-Income Countries: The Case of Jordan.
    Almomani E; Alabbadi I; Fasseeh A; Al-Qutob R; Al-Sharu E; Hayek N; Tarawneh MR; Kaló Z
    Value Health Reg Issues; 2021 Sep; 25():126-134. PubMed ID: 34015521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review.
    Chen Y; Carlson JJ
    J Manag Care Spec Pharm; 2022 Jan; 28(1):78-83. PubMed ID: 34949115
    [No Abstract]   [Full Text] [Related]  

  • 39. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
    Angelis A; Lange A; Kanavos P
    Eur J Health Econ; 2018 Jan; 19(1):123-152. PubMed ID: 28303438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementing managed entry agreements in practice: The Dutch reality check.
    Makady A; van Veelen A; de Boer A; Hillege H; Klungel OH; Goettsch W
    Health Policy; 2019 Mar; 123(3):267-274. PubMed ID: 30316540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.